Economics of Innovation
OHE conducts multi-disciplinary research to support sustainable incentives for health technology development that advances patient care and maximises the value of innovation for society.
We use mixed-methods approaches to examine regulatory policy design; new and alternative pathways for clinical development and evidence generation; innovative pricing and financing models that sustain R&D investment; and the impact of market design. Our work encompasses the perspectives of patients, industry, investors, payers, healthcare system decision makers, and policymakers. We maintain a global outlook, recognising that the health technology industry is international and that national, regional, and global policies together shape the economics of innovation.
Key objective for this research theme
- Generating evidence to support supply-side incentives that optimise health technology R&D
- Evaluating and advancing demand-side pricing and reimbursement policies and levers that balance affordability, access and incentives for innovation.
- Improving our understanding of the broad health and wider social value of innovation, and work toward maximising this value in an efficient and sustainable way.
Our latest content on this theme
Global rare‑disease policy shifts: what are the implications for equitable access to orphan medicines?
Rare diseases may affect only a small number of people, but together they impact an estimated 300–400 million people worldwide — and only around 5% have an approved treatment. As global attention grows, including the WHO’s upcoming 10-year Global Action Plan, it is important to understand how regulation, HTA, and pricing policies across the UK, EU, and US influence the development of orphan medicines and access for patients.
The commercial case for investing in ALS
Amyotrophic lateral sclerosis (ALS) is a rare, rapidly progressive neurodegenerative disease with devastating clinical and economic consequences.
OHE’s submission to a parliamentary inquiry on UK drug shortages
The following is an extract from OHE’s written submission to parliament focused on diversifying suppliers and recognising the value of treatment alternatives to mitigate this issue.
Taking STRIDES: The value of diagnostics against AMR
Addressing a critical gap in AMR policy and evaluation Antimicrobial resistance (AMR) is a global health crisis, projected to cause up to 10 million deaths annually…